#1P 蒜 药明康德 Wuxi AppTec 2023 Wuxi AppTec Investor Day Wuxi ATU: A Global CTDMO Platform Edward Hu Vice Chairman & Global Chief Investment Officer CEO of WuXi ATU#2Forward-Looking Statements This presentation may contain certain "forward-looking statements" which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our management. Although we believe that our predictions are reasonable, future events are inherently uncertain and our forward-looking statements may turn out to be incorrect. Our forward-looking statements are subject to risks relating to, among other things, the ability of our service offerings to compete effectively, our ability to meet timelines for the expansion of our service offerings, our ability to protect our clients' intellectual property, unforeseeable international tension, competition, the impact of emergencies and other force majeure. Our forward-looking statements in this presentation speak only as of the date on which they are made, and we assume no obligation to update any forward-looking statements except as required by applicable law or listing rules. Accordingly, you are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section. All information provided in this presentation is as of the date of this presentation and are based on assumptions that we believe to be reasonable as of this date, and we do not undertake any obligation to update any forward-looking statement, except as required under applicable law. 2 Non-IFRS Financial Measures We provide non-IFRS gross profit and non-IFRS net profit attributable to owners of the Company, which exclude share-based compensation expenses, listing expenses and issuance expenses of convertible bonds, fair value gain or loss from derivative component of convertible bonds, foreign exchange-related gains or losses and amortization of intangible assets acquired in business combinations, non-financial assets impairment, etc. We also provide adjusted non-IFRS net profit attributable to owners of the Company and earnings per share, which further exclude realized and unrealized gains or losses from our venture capital investments and joint ventures. Neither of above is required by, or presented in accordance with IFRS. We believe that the adjusted financial measures used in this presentation are useful for understanding and assessing our core business performance and operating trends, and we believe that management and investors may benefit from referring to these adjusted financial measures in assessing our financial performance by eliminating the impact of certain unusual, non-recurring, non-cash and non-operating items that we do not consider indicative of the performance of our core business. Such non-IFRS financial measures, the management of the Company believes, is widely accepted and adopted in the industry the Company is operating in. However, the presentation of these adjusted non-IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with IFRS. You should not view adjusted results on a stand-alone basis or as a substitute for results under IFRS, or as being comparable to results reported or forecasted by other companies. 药明康德 ? Wuxi AppTec#3Cell and Gene Therapy is a New Frontier in Medicine with a Potential to Provide Curative Medicines for Patients Cost per treatment Patients treated ww DOC XXX Nascent From academic to industry settings Early manufacturing: small scale, manual Early trials with limited patient group 2010 and disease area 2015 Cell therapy Use of living (modified or unmodified) cells to boost immunoreaction, repair, replace, or regenerate damaged tissue or treat diseases Growth 2020 Maturity Improved efficacy and understanding of safety events with broad clinical applications beyond cancers and rare diseases Global manufacturing and distribution 2025 Gene therapy Introduction, removal, or alteration of genetic material within patients to treat or prevent disease. 2030 ? Wuxi AppTec 药明康德#4Outlook of Cell & Gene Therapy Market Size Billion USD Historical and Forecasted Market Size of Global CGT Market, 2018-2030E Period 2018-2022 CAGR 86.6% 2022-2026E 54.9% 2026E-2030E 26.1% 81.8 68.9 56.7 45.0 32.3 22.3 13.9 0.5 1.2 2.1 8.8 5.6 3.5 2018 2019 2020 2021 2022 2023E 2024E 2025E 2026E 2027E 2028E 2029E 2030E Source: Frost & Sullivan analysis 药明康德 ? Wuxi AppTec#5FDA Approval of Cell and Gene Therapy Products are Growing • As of 1H 2023, there are total 32 FDA-approved cell and gene therapies. It is expected that cell and gene therapy will make big advances in the next few years, especially for diseases with short-term mortality in the next 5 to 10 years. 3 2 2 1 FDA Approved Cell and Gene Therapies, 2010-1H 2023 1 3 3 1 1 1 5 4 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 1H 2023 *As of 2023/6/30 Source: FDA, Frost & Sullivan analysis 3 药明康德 Wuxi AppTec#6Globally since 2017, a Total of 34 CGT Therapies Have Received Their First- time Approval CGT drugs which obtained 1st time approval, including approvals from ex-US regulatory authorities since 2017 8 ■Cell therapy (non-gene-modified) Gene-modified cell therapy 7 Gene therapy 6 LO 4 3 2 1 0 LUXTURNA GINTUIT Delytact Abecma ADSTILADRIN skysona Upstaza Elevidys Relma-cel HEMGENIX Cetranacogene dezaparvovec-drib Vyjuvek KYMRIAH HPC cord blood YESCARTA (axicabtagene cila eucel) Stemirac Collategene libmeldy™ Breyanzi (atidarsagene autotemcel) OrthoACIT Stempeucel 2017 Source: Public information 2018 Rosmir zynteglo TECARTUS StrataGraft™ ALOFISEL zolgensma Nepic RETHYMIC™ 2019 2020 2021 2022 ROCTAVIAN Lantidra EBVALLO tabelecie cel CARVYKTI (citacabtagene autoleuce Omisirge® Vyznova ビズノバ 2023 ニ 药明康德 Wuxi AppTec#7Over 4,000 Clinical and Preclinical Pipelines are Under Investigation, with Growing New Registered Clinical Trials Every Year Number of pipelines (PCC and clinical) in study by category Number of new clinical CGT trials by year 600 Gene therapy 500 1,800 Cell therapy BLA/ approval 1,600 1,400 400 1,200 Clinical 1,000 300 800 200 600 PCC/ 400 IND 100 200 0 0 T cells Stem cells NK cells Dendritic Macro- cells phages Others Gene Gene therapy editing Source: PharmCube NextPharma database; Date cutoff 06/2023; ASGCT Currently 2,328 clinical trials registered Ph37 Ph2/3 Ph2 Ph1/2 Ph1 2017 2018 2019 2020 2021 2022 2023 药明康德 ? Wuxi AppTec#8Cell therapy: CAR-T is by far the Most Popular Modality Currently Focused on Hematological Malignancies, Solid Tumor Targets and Autoimmune Disease Targets are also being Pursued Cell therapy pipeline breakdown by cell type and phase BLA/ approval 1,200 Ph3 Ph2/3 1,000 Ph2 Ph1/2 800 Ph1 Modified T cells Unmodified T cells NK cells 600 IND 400 PCC 200 0 Source: Pharm Cube NextPharma database; Date cutoff 05/2023 CAR-T TCR-T CAR-VOT CAR-Treg CAR-CIK TCR-YOT TIL Treg убт CIK Others CAR-NK NK Macrophages TCR-NK CAR-M Macrophage Dendritic cells Pipeline breakdown by target 0% 2% 4% 6% 8% CD19 BCMA CD22 CD20 CD33 CD123 DC Hematological malignancies CD7 CLL-1 CD38 MSLN HER2 GPC3 EGFR NY-ESO-1 CLDN18.2 CD70 Solid tumour B7-H3 EBV KARS PSMA 3 药明康德 Wuxi AppTec#9Gene therapy: AAV is by far the Most Popular Gene Delivery Vehicle; Rare Diseases and Retinal Diseases are Common Targeted Indications Gene therapy pipeline breakdown by cell type and phase 1200 BLA/ approval 1000 Ph3 Ph2/3 Ph1/2 Ph2 800 Ph1 IND 600 400 PCC Majority AAV-based 200 0 Conventional gene therapy Gene editing Others Source: PharmCube NextPharma database; Date cutoff 05/2023 Pipeline breakdown by indication 0% 2% 4% ALS DMD WAMD Hemophilia A Retinitis pigmentosa Parkinson's disease AMD Cystic fibrosis Alzheimer's disease Hemophilia B Leber's congenital... Friedreich's ataxia SMA A1AT-deficiency Pompe disease Stargardt's disease Diabetic macular edema 3 药明康德#10Future Outlook: Pipeline Products Pending Approval in Near Future will be a Key Driver for Future Sales Growth Gene therapy & gene editing B-Vec (HSV-1) Krystal Bio Upstaza (AAV) PTC Therapeutics Fidanacogene elaparvovec (AAV) SRP-9001 (AAV) Sarepta Therapeutics Roctavian (AAV) BioMarin Pfizer CTX-001 (ex vivo CRISPR/Cas) CRISPR & Vertex Lumevoq (AAV) GenSight bb1111 (lentivirus) Bluebird Bio EtranaDez* (AAV) uniQure & CSL Behring Cell therapy Omidubicel (allogenic HSC) Gamida Cell ACE-02 (autologous epidermis) J-TEC Lantidra (pancreatic islet cells) CellTrans NurOwn (MSC) BrainStorm Lifileucel (TIL) lovance Tab-Cel (allogeneic T-cell) Atara Bio Libmeldy (autologous HSC) Orchard Therapeutics HPC cord blood (UCB HPC) StemCyte SB623 (MSC) Sumitomo Pharma Afami-cel (TCR-T) Adaptimmune Therapeutics. CT-053 (CAR-T) CARsgen Therapeutics Inaticabtagene autoleucel (CAR-T) Juventas Legend Note: *Approved by FDA in 2022 under the name of Hemgenix; pending EU approval Source: The Alliance for Regenerative Medicine, public information Approved by FDA in 2023 Pending approval 老药明康德 Wuxi AppTec#11Historical and Forecasted Global Market Size of Cell and Gene Therapy CDMO, 2015-2032E Global cell and gene therapy CDMO services market increases from USD0.8 billion in 2015 to USD3.9 billion in 2022 with a CAGR of 24.6%. The market will continue to grow to USD11.6 billion by 2027 with a CAGR of 24.4% from 2022 to 2027. It's expected to reach USD42.5 billion in 2032 with a CAGR of 29.7% from 2027 to 2032. Historical and Forecasted Global Market Size of Cell and Gene Therapy CMO/CDMO, 2015-2032E ROW China Period US EU5 Total based 2015-2022 27.1% 23.3% 25.9% 18.2% 24.6% 2022-2027E 25.5% 23.2% 24.7% 21.8% 24.4% 2027E-2032E 29.0% 28.9% 37.1% 29.0% 29.7% 42.5 33.2 25.9 20.0 15.3 Billion USD 11.6 8.8 6.8 3.4 3.9 4.6 5.5 0.8 1.0 1.2 1.5 1.9 2.3 2015 2016 2017 2018 2019 2020 2021 2022 2023E 2024E 2025E 2026E 2027E 2028E 2029E 2030E 2031E 2032E ■ US EU5 China based ROW Note: Cell and Gene Therapies include mRNA and its plasmid, but oligonucleotides or Gene detection are not included. Source: Frost & Sullivan analysis 药明康德 ? Wuxi AppTec#12Global Competitive Landscape of CGT CDMO Market Players 2022 Unit: Million USD 1.7% 3.4% 3.8% 4.2% 4.4% WuXi ATU Global Competitive Landscape of WuXi AppTec - Wuxi ATU Corresponding Service Market Players, 2022 Market Company Revenue Share 18.0% Company A 1,701.1 38.5% Company B 725.7 16.4% 38.5% Company C 418.8 9.5% Γ | WuXi ATU 194.4 4.4% L Company E 187.0 4.2% Company F 166.2 3.8% Company G 152.5 3.4% Company H 76.9 1.7% 9.5% All Others 797.1 18.0% 16.4% Sources: Frost & Sullivan Analysis ? Wuxi AppTec 药明康德#13WuXi ATU - A Globally Integrated CTDMO Research & Discovery "Enabling DNA to BLA" Development, Manufacturing, & Testing 13 DISCOVERY Preclinical Biomanufacturing Pre-IND Phase I Phase II Phase III BLA/Commercial Three business engines fueled by global platforms Advanced technologies, manufacturing and testing solutions for cell and gene therapy innovators Viral Vectors AAV | LVV | HSV | Adeno | Plasmids Cell Therapies CAR-T❘ TIL | MSC Testing Integrated and standalone advanced therapy and biologics testing 4 sites across 3 continents | 75k+ square meters facilities | 1,200+ employees 2500+ cell therapy GMP lots released ? Wuxi AppTec 药明康德#14Global Sites of Wuxi ATU League Island 1 82,000 ft² League Island 2 150,000 ft² 4701 Commerce Center 3 55,000 ft² Rouse 400 140,000 ft² DM Oxford, UK 26,000 ft² RD Wuxi City, Jiangsu 143,000 ft² LinGang, Shanghai 231,000 ft² |D|M Biopolis (A*star) Singapore 2,000 ft² DM DT Tuas, Singapore 250,000 ft² (e2027) DASA R MT DMT WGQ, Shanghai 6,600 ft² Research Testing Development Manufacturing DT D 药明康德 ? Wuxi AppTec#15Wuxi ATU Philadelphia Campus Over 400,000 sq ft Global Compliance - Comprehensive Quality System Integrated Testing and Manufacturing Operations 3004 药明康德 ? Wuxi AppTec#16Expanding CTDMO Pipeline Drives Strong Growth Ahead "T" 167 Testing Customers (TTM) I I Autolo- I Allo- gous CAR-T I genic I CAR-T In-vivo CAR-T Allograft Cell TIL Viral Vector Others 1 Therapy 17 9 7 1 2 12 4 52 Preclinical & Phase I "D" 5 2 2 1 10 Phase II 2 3 1 1 7 Phase III "M" To come in Commercial 2023 2H ? Wuxi AppTec 药明康德#17Complex CGT Products Requires Sophisticated Testing, Development and Manufacturing all under One Roof for Efficiency, Reliability and Cost Donor material processing Cell phenotype sorting Cell expansion Transfection Cell wash/formulation T Cell Purification T Cell Transduction T Cell Expansion Product Formulation Product QC Product Release Patient Leukapheresis PBMC Isolate | Vein to Vein Time 18-30 days Our CTDMO platform offers customers: / One stop service for integrated development, manufacturing and testing that ensures vein-to-vein timeline for patients. / Strong regulatory and technical expertise, with dedicated process and analytical development teams / In-stock raw materials and consumables with established batch records and testing protocols / Full in-process and release testing, plus complete quality control and characterization services / Support customers from IND to BLA to commercialization ? Wuxi AppTec 药明康德#18Testing Poses Complexity and Challenges to the CGT Industry · Testing evolution from Small Molecules to Advanced Therapies B Vaccine COVID.19 • Testing Platforms for CAR-T Products Product specific release tests: CAR Expression by Flow Cytometry Integrated Copy Number (GOI specific) General characteristics: • Cell Count and Viability by NC-200 Additional Capabilities (as needed): . Potency Assays (product specific) . . T-cell Memory Phenotype by Flow Cytometry T-Cell Activation by Flow Cytometry T-Cell Exhaustion by Flow Cytometry XXXXX . Small Molecule Testing • Simple chemical/physical characterization Conventional instruments in traditional QC labs • • In Vitro and PCR based adventitious agents Residual Viral DNA 1e3 -Cellular Events :63.24%-#:.. CD4+CD8- 50.41%-# CD4+CD8+ 2.89%-# 1000- 750 1e2 • Identity by Flow Cytometry • Cellular Impurities by Flow Cytometry Safety Testing: 1000 • Sterility, Endotoxin, Mycoplasma • Replication Competent Virus 500 250 . 750- CD4+ CAR+ 57.31%-# 1e1 CD4-C 40.55% 500- CD4-CD8- 6.15%-# 250 0 0 250 500 750 1000 -101 1e1 1e2 1e3 -1 0 1 1e1 1e2 1e3 Advanced Therapy Testing • • Complex biologics, viral and cell characterization Advanced instrumentation in development labs Broadly used cell based assays (potency assays) ? Wuxi AppTec 药明康德#19Wuxi ATU Manufacturing Platform Roadmap Defining CGT Future Manufacturing Standard to Drive Down Cost Automate & Scale Up Collaborating with automation companies to develop fully automated cell manufacturing system Innovate & Create ATU internally develops closed system for cell manufacturing Improve & Optimize Clients' process transferred to ATU and ATU improve and optimize the process for GMP manufacturing & testing السا $ 000 Drove down mfg cost by 40% for a cell therapy product from clinical scale to commercial scale mfg ⚫ For a viral vector product, reduced mfg cost by >50% Using TESSA technology, we can drive down AAV mfg cost by 10 folds per dose#20Manufacturing Platforms for CGT Improve & optimize industry standard manufacturing platforms Innovate & create new CGT manufacturing platforms WuXi ATU Platform Triple Transfection Platform 4-Plasmid Transfection Platform Cell Therapy Manufacturing Platforms R&D Objective Improve the plasmids, cell line and process, whilst standardizing the platform Improve processes to increase yield and activity R&D Outcome Industry-leading manufacturing performance with current industry standard platforms TESSATM Technology for AAV Vectors Lenti VV Stable Cell Line for Lentiviral Vectors Validate new technologies at scale and support customers transition to new platforms Transforming manufacturing performance with innovative new platforms 药明康德 ? Wuxi App Tec#21Innovate Lenti Viral Vector Stable Technology VSV-G GagPol C Co GOI Cove Cona Rev Transfection HEK293 cells VSV-G GagP Rev HEK293 cells GOI + Induction agent Our Vision Provide a lentiviral manufacturing platform that mimics the CHO cell line platform used for commercial monoclonal antibody production Lentiviral particles Transient lentiviral manufacturing process Lentiviral particles Producer cell line (no plasmids) ? Wuxi AppTec 药明康德#22Infectious titre TU/mL) 1.0E+09 Lenti VV Stable Platform Delivers Consistent High Yields for Therapeutically Relevant Genes 1.0E+08 1.0E+07 1.0E+06 GFP Lenti VV Packaging cell line productivity with therapeutically relevant GOls shRNA T Factor VIII CAR-CD19 Infectious titre TU/mL 1.E+06 1.E+07 1.E+08 1.E+09 Neg GFP shRNA Lenti VV Producer pool productivity with therapeutically relevant GOIs CAR-CD19 CAR-BCMA PKLR Cas9 Stag2Cas9 FANCA Factor VIII ? Wuxi AppTec 药明康德#23Innovative & Versatile Processes to Meet Clients' Needs for Speed and Costs for AAV Manufacturing TESSA Hybrid TESSA Pro TESSA Single AAV PLASMID GENE OF INTEREST & AAV GENOME TESSA VECTOR ENCODING REP & CAP GENES AAV PARTICLES ENCODING CUSTOM GOI TESSA VECTOR ENCODING REP & CAP GENES TESSA VECTOR ENCODING REP & CAP GENES GOI REP GOL CAP GOI Infection Infection Infection MX HEK293 cells Production MX REP CAP Infection HEK293 cells Production GOI GOI GOI GOI GOI GO GOI GOI GOI GOI GO GOI REP CAP Infection GOI HEK293 producer cells Production GOI GO GOI GOI GOI GOI 药明康德 ? Wuxi AppTec#24The Future of Viral Vector Manufacturing Standard is Here! Current viral vector manufacturing approaches require large quantities of expensive plasmids Current methods struggle to scale above 200L Esinors sledk .000 sartoriusstedim Plasmid-Free, Fully Scalable Manufacturing of Lentiviral Vectors (LVV) & Adeno-Associated Virus (AAV) 200L Bioreactor 1000L Bioreactor Our technologies remove the need for plasmids and reduce the costs of manufacturing Our new technologies can be scaled >2000L ? Wuxi AppTec 药明康德#25Accelerated Timelines to IND CAR-T (CMC) traditional INDexpress Viral Vectors (CMC) traditional INDexpress 6 months 10 months 8-9 months Full Services (CMC + Preclinical) traditional • Projects will be able to leverage ATU's experience to identify your unique short- path to IND approval. Global manufacturing sites to best- accommodate to the relevant regional regulatory guidance(s). 8-14 months • Dedicated facilities infrastructure and resources for INDexpress projects. • All analytical testing methods and release assays are included (ATU-qualified and - validated assays). 20+ months • Devoid of extensive lead times for INDexpress 15 months Full Services Package*: AAV, full IND package, includes GLP tox and bioanalytical assays, full regulatory submission programs in cell therapies, viral vectors and plasmid synthesis. Seamlessly move into GMP manufacturing 药明康德 ? Wuxi AppTec#26Solution-Centric Portfolio: from DNA to IND to BLA for Cell & Gene Therapies Leverage the entire WuXi AppTec service portfolios for the development of advanced therapies WUXI ADVANCED THERAPIES 药明生基 P 药明康德 Wuxi AppTec + Discovery Biology Pharmacology Clinical CMC Manufacture Plasmid Synthesis ● ● AAV Production Cell Therapies Project Management ● DS Production DP Production • CGT Testing Regulatory Filing Tox and Safety Bioanalysis 3 药明康德 Wuxi AppTec Biology & Testing • ● Pharmacology Safety Toxicology Biodistribution Bioanalysis Clinical Trial Services • in vitro Potency Submission Services ● N ? Wuxi AppTec 药明康德#27IND Express: Cell Therapy (w/ plasmid and LVV) Company A . IND Express Case in Progress for Investigator Initiated Trial ("IIT") Purpose in China 2*TCRT IIT in 11 Months (from Plasmid to Cell Therapy Product) • ATU will provide CDMO Services for Company "SR" 2*TCRT IIT project: - 2*GOI Plasmid: PCB banking, Demo and Verification run, ENG (IIT) run 2*GOI LVV: DoE, Demo, 2*Verification, IIT run 2*GOI TCRT: MOI study, Process optimization, APS, ENG and IIT run • IND Express Strategy - Adopt overlapping execution by risk assessment to shorten the project line Fully integrated PD/AD, clinical MFG and QC to enable IIT batch manufacture and release testing Incoming SOW DoE V-run PTP TT to MSAT/MFG TTSR APS/IIT Runs PD ownership PD/MFG/MSAT ownership Activity Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Plasmids TCRT 0 2023-0 GOI ENG/TST GOI#1 LVV IIT/TST GOI#2 LVV IIT/TST 23-07-25 GOI#1 TCRT IIT GOI#2 TCRT IIT ? Wuxi AppTec 药明康德#28Near Term Growth Catalysts with Four Commercial Products to be Launched in 2023/2024 TIL: IND to BLA ✓ 2015-Present ✓ 450+ Clinical Batches ✓ 1000+ Potency Tests ✓ Commercial Supply at more than 300 batches / year starting late 2023 Plasmid & LVV: IND to BLA 2018-Present ✓ 8 Months from project start to IND ✓ CDE on-site inspection completed in March 2023 ✓ Commercial Supply to start upon NMPA approval CAR-T: To Provide Commercial Supply ✓ 2023-Present ✓ Tech transfer to PAS filing 14 months ✓ Commercial Supply Launch at 1000+ batches/year starting 2H-2024 ✓ Ramping up to more batches / year by 2026 ✓ LVV: Commerical Supply for CAR-T 2020-Present ✓ PPQ in progress ✓ Post PPQ supply starting in early 2024 ✓ FDA PAI submission in 1H 2024 ✓ Commercial supply at 40-120 batches / year starting 2H-2024 Full Regulatory Support for IND/BLA Filing; PLI (Inspection) Readiness Leading to Commercialization ? Wuxi AppTec 药明康德#29Wuxi ATU Quality and Regulatory Consistently Deliver Quality Compliance & Regulatory Services 2023 H1 Highlights FDA U.S. FOOD & DRUG ADMINISTRATION Audit and Inspections 国家药品监督管理局 National Medical Products Administration Inspection & Certification: 2 Client & Internal Audit: 45 1st health authority inspection for the China facility; pre- licensure inspection for US facility scheduled in Q3-2023 Client Submission Support (US, EU & CN) • Pre-IND: 3 • IND: 6 . BLA: 3 ilac-MRA 6 IND approved in 2023 H1 ■ US Philadelphia FEI #1000122198; Active Type V DMF for all four facilities China Huishan FEI #3017796768 Recent Inspection/Certification March 2023; NMPA (China) Inspection March 2023; ISO 17025 Re-certification August 2022; USDA Inspection March 2022; TGA (Australia) GMP Inspection December 2021; EMA GMP Inspection June 2021; USDA Inspection February 2021; ISO 17025 Re-certification January 2020; FDA GMP Inspection December 2019; EMA GMP Inspection March 2019; TGA (Australia) GMP Inspection March 2019; PMDA (Japan) GCTP Inspection ? Wuxi AppTec 药明康德#30Wuxi ATU is Well Positioned to Transform CGT Industry to Reach its Full Potentials to Make CGT Products Affordable for Many Patients 01 Our integrated CTDMO model will drive strong growth in years to come and enable CGT industry efficiently develop and commercialize game changing therapies for patients in need WuXi ATU 50 05 02 Our technology and manufacturing platforms will continuously improve productivity and drive down manufacturing costs of CGT products 03 Our integrated testing, development and manufacturing platform enables us to meet very tight Vein-to-Vein turnaround time requirements for cell therapies 04 H TESSA and Stable Lenti-Cell Line technology will transform future AAV and LVV manufacturing Our track record and reputation of supporting customers to develop CGT products from DNA to IND to BLA and commercialization will enable us to grow strongly in years to come ? Wuxi AppTec 药明康德